English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 140 | Tables: 133 | Medical Care
The global Ex Vivo Skin Explants market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Ex Vivo Skin Explants are pieces of skin tissue that have been surgically removed from a living organism (human or animal) and maintained outside the body for research purposes. These explants retain the natural architecture and cellular composition of the original tissue, making them valuable for studying various aspects of skin biology, pharmacology, toxicology, and disease mechanisms. Ex vivo skin explants are used to evaluate the effects of drugs, chemicals, and biological agents on skin responses, providing insights into normal and pathological skin conditions.
From a downstream perspective, Pharmaceutical accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Ex Vivo Skin Explants leading manufacturers including Genoskin, MatTek Life Sciences, Creative Bioarray, EpiSkin, Reprocell, Alcyomics, Epistem, QIMA Life Sciences, Extherid Biosciences, Perfectus Biomed, etc., dominate supply; the top five capture approximately % of global revenue, with Genoskin leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Ex Vivo Skin Explants market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Genoskin
MatTek Life Sciences
Creative Bioarray
EpiSkin
Reprocell
Alcyomics
Epistem
QIMA Life Sciences
Extherid Biosciences
Perfectus Biomed
Xenometrix
Syntivia
Creative Biolabs
Segment by Type
Human Skin Explants
Animal Skin Explants
Segment by Application
Pharmaceutical
Cosmetic
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Ex Vivo Skin Explants study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Ex Vivo Skin Explants: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Ex Vivo Skin Explants Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Human Skin Explants
1.2.3 Animal Skin Explants
1.3 Market Segmentation by Application
1.3.1 Global Ex Vivo Skin Explants Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical
1.3.3 Cosmetic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Ex Vivo Skin Explants Revenue Estimates and Forecasts 2020-2031
2.2 Global Ex Vivo Skin Explants Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Ex Vivo Skin Explants Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Ex Vivo Skin Explants Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Human Skin Explants Market Size by Players
3.3.2 Animal Skin Explants Market Size by Players
3.4 Global Ex Vivo Skin Explants Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Ex Vivo Skin Explants Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Ex Vivo Skin Explants Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Ex Vivo Skin Explants Market Size by Type (2020-2031)
6.4 North America Ex Vivo Skin Explants Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Ex Vivo Skin Explants Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Ex Vivo Skin Explants Market Size by Type (2020-2031)
7.4 Europe Ex Vivo Skin Explants Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Ex Vivo Skin Explants Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Ex Vivo Skin Explants Market Size by Type (2020-2031)
8.4 Asia-Pacific Ex Vivo Skin Explants Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Ex Vivo Skin Explants Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Ex Vivo Skin Explants Market Size by Type (2020-2031)
9.4 Central and South America Ex Vivo Skin Explants Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Ex Vivo Skin Explants Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Ex Vivo Skin Explants Market Size by Type (2020-2031)
10.4 Middle East and Africa Ex Vivo Skin Explants Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Ex Vivo Skin Explants Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Genoskin
11.1.1 Genoskin Corporation Information
11.1.2 Genoskin Business Overview
11.1.3 Genoskin Ex Vivo Skin Explants Product Features and Attributes
11.1.4 Genoskin Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.1.5 Genoskin Ex Vivo Skin Explants Revenue by Product in 2024
11.1.6 Genoskin Ex Vivo Skin Explants Revenue by Application in 2024
11.1.7 Genoskin Ex Vivo Skin Explants Revenue by Geographic Area in 2024
11.1.8 Genoskin Ex Vivo Skin Explants SWOT Analysis
11.1.9 Genoskin Recent Developments
11.2 MatTek Life Sciences
11.2.1 MatTek Life Sciences Corporation Information
11.2.2 MatTek Life Sciences Business Overview
11.2.3 MatTek Life Sciences Ex Vivo Skin Explants Product Features and Attributes
11.2.4 MatTek Life Sciences Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.2.5 MatTek Life Sciences Ex Vivo Skin Explants Revenue by Product in 2024
11.2.6 MatTek Life Sciences Ex Vivo Skin Explants Revenue by Application in 2024
11.2.7 MatTek Life Sciences Ex Vivo Skin Explants Revenue by Geographic Area in 2024
11.2.8 MatTek Life Sciences Ex Vivo Skin Explants SWOT Analysis
11.2.9 MatTek Life Sciences Recent Developments
11.3 Creative Bioarray
11.3.1 Creative Bioarray Corporation Information
11.3.2 Creative Bioarray Business Overview
11.3.3 Creative Bioarray Ex Vivo Skin Explants Product Features and Attributes
11.3.4 Creative Bioarray Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.3.5 Creative Bioarray Ex Vivo Skin Explants Revenue by Product in 2024
11.3.6 Creative Bioarray Ex Vivo Skin Explants Revenue by Application in 2024
11.3.7 Creative Bioarray Ex Vivo Skin Explants Revenue by Geographic Area in 2024
11.3.8 Creative Bioarray Ex Vivo Skin Explants SWOT Analysis
11.3.9 Creative Bioarray Recent Developments
11.4 EpiSkin
11.4.1 EpiSkin Corporation Information
11.4.2 EpiSkin Business Overview
11.4.3 EpiSkin Ex Vivo Skin Explants Product Features and Attributes
11.4.4 EpiSkin Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.4.5 EpiSkin Ex Vivo Skin Explants Revenue by Product in 2024
11.4.6 EpiSkin Ex Vivo Skin Explants Revenue by Application in 2024
11.4.7 EpiSkin Ex Vivo Skin Explants Revenue by Geographic Area in 2024
11.4.8 EpiSkin Ex Vivo Skin Explants SWOT Analysis
11.4.9 EpiSkin Recent Developments
11.5 Reprocell
11.5.1 Reprocell Corporation Information
11.5.2 Reprocell Business Overview
11.5.3 Reprocell Ex Vivo Skin Explants Product Features and Attributes
11.5.4 Reprocell Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.5.5 Reprocell Ex Vivo Skin Explants Revenue by Product in 2024
11.5.6 Reprocell Ex Vivo Skin Explants Revenue by Application in 2024
11.5.7 Reprocell Ex Vivo Skin Explants Revenue by Geographic Area in 2024
11.5.8 Reprocell Ex Vivo Skin Explants SWOT Analysis
11.5.9 Reprocell Recent Developments
11.6 Alcyomics
11.6.1 Alcyomics Corporation Information
11.6.2 Alcyomics Business Overview
11.6.3 Alcyomics Ex Vivo Skin Explants Product Features and Attributes
11.6.4 Alcyomics Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.6.5 Alcyomics Recent Developments
11.7 Epistem
11.7.1 Epistem Corporation Information
11.7.2 Epistem Business Overview
11.7.3 Epistem Ex Vivo Skin Explants Product Features and Attributes
11.7.4 Epistem Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.7.5 Epistem Recent Developments
11.8 QIMA Life Sciences
11.8.1 QIMA Life Sciences Corporation Information
11.8.2 QIMA Life Sciences Business Overview
11.8.3 QIMA Life Sciences Ex Vivo Skin Explants Product Features and Attributes
11.8.4 QIMA Life Sciences Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.8.5 QIMA Life Sciences Recent Developments
11.9 Extherid Biosciences
11.9.1 Extherid Biosciences Corporation Information
11.9.2 Extherid Biosciences Business Overview
11.9.3 Extherid Biosciences Ex Vivo Skin Explants Product Features and Attributes
11.9.4 Extherid Biosciences Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.9.5 Extherid Biosciences Recent Developments
11.10 Perfectus Biomed
11.10.1 Perfectus Biomed Corporation Information
11.10.2 Perfectus Biomed Business Overview
11.10.3 Perfectus Biomed Ex Vivo Skin Explants Product Features and Attributes
11.10.4 Perfectus Biomed Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Xenometrix
11.11.1 Xenometrix Corporation Information
11.11.2 Xenometrix Business Overview
11.11.3 Xenometrix Ex Vivo Skin Explants Product Features and Attributes
11.11.4 Xenometrix Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.11.5 Xenometrix Recent Developments
11.12 Syntivia
11.12.1 Syntivia Corporation Information
11.12.2 Syntivia Business Overview
11.12.3 Syntivia Ex Vivo Skin Explants Product Features and Attributes
11.12.4 Syntivia Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.12.5 Syntivia Recent Developments
11.13 Creative Biolabs
11.13.1 Creative Biolabs Corporation Information
11.13.2 Creative Biolabs Business Overview
11.13.3 Creative Biolabs Ex Vivo Skin Explants Product Features and Attributes
11.13.4 Creative Biolabs Ex Vivo Skin Explants Revenue and Gross Margin (2020-2025)
11.13.5 Creative Biolabs Recent Developments
12 Ex Vivo Skin ExplantsIndustry Chain Analysis
12.1 Ex Vivo Skin Explants Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Ex Vivo Skin Explants Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Ex Vivo Skin Explants Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Ex Vivo Skin Explants Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Ex Vivo Skin Explants Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Ex Vivo Skin Explants Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Ex Vivo Skin Explants Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Ex Vivo Skin Explants Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Ex Vivo Skin Explants Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Ex Vivo Skin Explants by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ex Vivo Skin Explants as of 2024)
Table 11. Global Ex Vivo Skin Explants Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Ex Vivo Skin Explants Companies Headquarters
Table 13. Global Ex Vivo Skin Explants Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Ex Vivo Skin Explants Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Ex Vivo Skin Explants Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Ex Vivo Skin Explants Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Ex Vivo Skin Explants Revenue by Application (2026-2031) & (US$ Million)
Table 21. Ex Vivo Skin Explants High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Ex Vivo Skin Explants Growth Accelerators and Market Barriers
Table 25. North America Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Ex Vivo Skin Explants Growth Accelerators and Market Barriers
Table 27. Europe Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Ex Vivo Skin Explants Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Ex Vivo Skin Explants Investment Opportunities and Key Challenges
Table 31. Central and South America Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Ex Vivo Skin Explants Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Ex Vivo Skin Explants Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Genoskin Corporation Information
Table 35. Genoskin Description and Major Businesses
Table 36. Genoskin Product Features and Attributes
Table 37. Genoskin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Genoskin Revenue Proportion by Product in 2024
Table 39. Genoskin Revenue Proportion by Application in 2024
Table 40. Genoskin Revenue Proportion by Geographic Area in 2024
Table 41. Genoskin Ex Vivo Skin Explants SWOT Analysis
Table 42. Genoskin Recent Developments
Table 43. MatTek Life Sciences Corporation Information
Table 44. MatTek Life Sciences Description and Major Businesses
Table 45. MatTek Life Sciences Product Features and Attributes
Table 46. MatTek Life Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. MatTek Life Sciences Revenue Proportion by Product in 2024
Table 48. MatTek Life Sciences Revenue Proportion by Application in 2024
Table 49. MatTek Life Sciences Revenue Proportion by Geographic Area in 2024
Table 50. MatTek Life Sciences Ex Vivo Skin Explants SWOT Analysis
Table 51. MatTek Life Sciences Recent Developments
Table 52. Creative Bioarray Corporation Information
Table 53. Creative Bioarray Description and Major Businesses
Table 54. Creative Bioarray Product Features and Attributes
Table 55. Creative Bioarray Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Creative Bioarray Revenue Proportion by Product in 2024
Table 57. Creative Bioarray Revenue Proportion by Application in 2024
Table 58. Creative Bioarray Revenue Proportion by Geographic Area in 2024
Table 59. Creative Bioarray Ex Vivo Skin Explants SWOT Analysis
Table 60. Creative Bioarray Recent Developments
Table 61. EpiSkin Corporation Information
Table 62. EpiSkin Description and Major Businesses
Table 63. EpiSkin Product Features and Attributes
Table 64. EpiSkin Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. EpiSkin Revenue Proportion by Product in 2024
Table 66. EpiSkin Revenue Proportion by Application in 2024
Table 67. EpiSkin Revenue Proportion by Geographic Area in 2024
Table 68. EpiSkin Ex Vivo Skin Explants SWOT Analysis
Table 69. EpiSkin Recent Developments
Table 70. Reprocell Corporation Information
Table 71. Reprocell Description and Major Businesses
Table 72. Reprocell Product Features and Attributes
Table 73. Reprocell Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Reprocell Revenue Proportion by Product in 2024
Table 75. Reprocell Revenue Proportion by Application in 2024
Table 76. Reprocell Revenue Proportion by Geographic Area in 2024
Table 77. Reprocell Ex Vivo Skin Explants SWOT Analysis
Table 78. Reprocell Recent Developments
Table 79. Alcyomics Corporation Information
Table 80. Alcyomics Description and Major Businesses
Table 81. Alcyomics Product Features and Attributes
Table 82. Alcyomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Alcyomics Recent Developments
Table 84. Epistem Corporation Information
Table 85. Epistem Description and Major Businesses
Table 86. Epistem Product Features and Attributes
Table 87. Epistem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Epistem Recent Developments
Table 89. QIMA Life Sciences Corporation Information
Table 90. QIMA Life Sciences Description and Major Businesses
Table 91. QIMA Life Sciences Product Features and Attributes
Table 92. QIMA Life Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. QIMA Life Sciences Recent Developments
Table 94. Extherid Biosciences Corporation Information
Table 95. Extherid Biosciences Description and Major Businesses
Table 96. Extherid Biosciences Product Features and Attributes
Table 97. Extherid Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Extherid Biosciences Recent Developments
Table 99. Perfectus Biomed Corporation Information
Table 100. Perfectus Biomed Description and Major Businesses
Table 101. Perfectus Biomed Product Features and Attributes
Table 102. Perfectus Biomed Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Perfectus Biomed Recent Developments
Table 104. Xenometrix Corporation Information
Table 105. Xenometrix Description and Major Businesses
Table 106. Xenometrix Product Features and Attributes
Table 107. Xenometrix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Xenometrix Recent Developments
Table 109. Syntivia Corporation Information
Table 110. Syntivia Description and Major Businesses
Table 111. Syntivia Product Features and Attributes
Table 112. Syntivia Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Syntivia Recent Developments
Table 114. Creative Biolabs Corporation Information
Table 115. Creative Biolabs Description and Major Businesses
Table 116. Creative Biolabs Product Features and Attributes
Table 117. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Creative Biolabs Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Ex Vivo Skin Explants Product Picture
Figure 2. Global Ex Vivo Skin Explants Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Human Skin Explants Product Picture
Figure 4. Animal Skin Explants Product Picture
Figure 5. Global Ex Vivo Skin Explants Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Pharmaceutical
Figure 7. Cosmetic
Figure 8. Others
Figure 9. Ex Vivo Skin Explants Report Years Considered
Figure 10. Global Ex Vivo Skin Explants Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 12. Global Ex Vivo Skin Explants Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Ex Vivo Skin Explants Revenue Market Share by Region (2020-2031)
Figure 14. Global Ex Vivo Skin Explants Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Human Skin Explants Revenue Market Share by Player in 2024
Figure 17. Animal Skin Explants Revenue Market Share by Player in 2024
Figure 18. Global Ex Vivo Skin Explants Revenue Market Share by Type (2020-2031)
Figure 19. Global Ex Vivo Skin Explants Revenue Market Share by Application (2020-2031)
Figure 20. North America Ex Vivo Skin Explants Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Ex Vivo Skin Explants Revenue (US$ Million) in 2024
Figure 22. North America Ex Vivo Skin Explants Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Ex Vivo Skin Explants Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Ex Vivo Skin Explants Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Ex Vivo Skin Explants Revenue (US$ Million) in 2024
Figure 29. Europe Ex Vivo Skin Explants Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Ex Vivo Skin Explants Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 32. France Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Ex Vivo Skin Explants Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Ex Vivo Skin Explants Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Ex Vivo Skin Explants Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Ex Vivo Skin Explants Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 44. India Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Ex Vivo Skin Explants Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Ex Vivo Skin Explants Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Ex Vivo Skin Explants Revenue (US$ Million) in 2024
Figure 52. Central and South America Ex Vivo Skin Explants Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Ex Vivo Skin Explants Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Ex Vivo Skin Explants Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Ex Vivo Skin Explants Revenue (US$ Million) in 2024
Figure 58. South America Ex Vivo Skin Explants Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Ex Vivo Skin Explants Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Ex Vivo Skin Explants Revenue (2020-2025) & (US$ Million)
Figure 64. Ex Vivo Skin Explants Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
